^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Kymriah (tisagenlecleucel-T)

i
Company:
Novartis, University of Pennsylvania
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
3d
MT2017-45: CAR-T Cell Therapy for Heme Malignancies (clinicaltrials.gov)
P2, N=144, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Phase classification: P --> P2
Phase classification
|
CD19 (CD19 Molecule)
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel)
8d
Neurotoxicity in Patients With CNS Lymphomas Treated With CAR T-Cell Therapy: A Study From the French Oculo-Cerebral Lymphoma Network. (PubMed, Neurology)
Although the rate of neurotoxicity seems acceptable in CNS lymphomas, the risk of unusual prolonged neurologic deterioration is high in patients with grade 3-4 neurotoxicity. Special attention should be given to older patients with cognitive impairment who seem at greater risk of severe forms of neurotoxicity. Larger series are warranted to confirm these results.
Retrospective data • Journal
|
IL10 (Interleukin 10)
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T)
11d
REFUEL: A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) (clinicaltrials.gov)
P2, N=30, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed
|
CD19 (CD19 Molecule) • IFNG (Interferon, gamma)
|
Kymriah (tisagenlecleucel-T)
1m
Targeting PRC2 Enhances the Cytotoxic Capacity of Anti-CD19 CAR-T Cells Against Hematological Malignancies. (PubMed, Cancer Res)
A gene signature derived from in-house PRC2-inhibited 19BBζ CAR-T cells was enriched in tisagenlecleucel (tisa-cel) BBζ CAR-T cell therapy responders with large B-cell lymphoma. Collectively, these results demonstrate that targeting PRC2 may be a promising approach to enhance a functional effector program in CAR-T cells to improve the efficacy in treating hematological malignancies.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • GZMB (Granzyme B)
|
Kymriah (tisagenlecleucel-T)
2ms
CAR T-cell Therapy Landscape in Pediatric, Adolescent and Young Adult Oncology - A Comprehensive Analysis of Clinical Trials. (PubMed, Crit Rev Oncol Hematol)
In the pediatric, adolescent, and young adult (P-AYA) populations, Tisagenlecleucel (Kymriah®) exemplifies the success of CAR T-cell therapy, demonstrating significant efficacy in treating relapsed or refractory acute lymphoblastic leukemia (r/r ALL)...Addressing these barriers is critical for advancing CAR T-cell therapy in pediatric oncology, improving outcomes, and ensuring equitable access to innovative treatments for these vulnerable populations. This review aims to inform future research and policy decisions, promoting advancements in CAR T-cell therapy for P-AYA cancer patients.
Review • Journal
|
CD276 (CD276 Molecule) • CD22 (CD22 Molecule)
|
Kymriah (tisagenlecleucel-T)
2ms
Orphan Indications for CD19 Redirected Autologous T Cells (clinicaltrials.gov)
P2, N=133, Recruiting, Stephan Grupp MD PhD | N=81 --> 133
Enrollment change
|
CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A)
|
Kymriah (tisagenlecleucel-T)
2ms
Study of Out of Specification for Tisagenlecleucel (clinicaltrials.gov)
P3, N=200, Recruiting, Novartis Pharmaceuticals | Trial completion date: Apr 2025 --> Mar 2026 | Trial primary completion date: Apr 2025 --> Mar 2026
Trial completion date • Trial primary completion date
|
Kymriah (tisagenlecleucel-T)
2ms
Long-term Follow up Local Registry Study of Kymriah in South Korea (clinicaltrials.gov)
P=N/A, N=500, Not yet recruiting, Novartis Pharmaceuticals
New trial
|
Kymriah (tisagenlecleucel-T)
2ms
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study (clinicaltrials.gov)
P1, N=4, Completed, Emory University | Recruiting --> Completed | N=20 --> 4 | Trial completion date: Aug 2025 --> Sep 2024 | Trial primary completion date: Aug 2024 --> Mar 2024
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
CD27 (CD27 Molecule)
|
Copiktra (duvelisib) • Kymriah (tisagenlecleucel-T) • ETP-47187
3ms
Chimeric Antigen Receptor (CAR) T-cell Therapy in the Treatment of Diffuse Large B-cell Lymphoma (DLBCL): A Systematic Review. (PubMed, Cureus)
The review highlights that CAR T-cell therapies, mainly tisagenlecleucel (Tisa-cel) and axicabtagene ciloleucel (Axi-cel), have shown superior effectiveness in comparison to standard chemotherapy in patients with relapsed or refractory DLBCL. Lisocabtagene maraleucel (Liso-cel) showed significant improvement outcomes in event-free and progression-free survival. However, CAR T-cell therapies are associated with many side effects. The most common side effects include hematologic toxicity, prolonged neutropenia, and infections, while clinical outcomes are highly impacted by many factors, which include a pro-inflammatory state, PPM1D gene mutation, infusion timing, and circulating monocytes.
Clinical • Review • Journal
|
PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D)
|
PPM1D mutation
|
Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T)
3ms
Role of procalcitonin, C reactive protein and ferritin in cytokine release syndrome after CAR T-cell therapy in children and young adults. (PubMed, Biomarkers)
Our goal is to elucidate the role of procalcitonin (PCT), C-reactive protein (CRP) and ferritin in the context of CRS following CAR T-cell infusion to predict its severity and PICU admission.MethodsProspective observational study (2016-2022) in children and young adult who received CAR T-cell therapy (Tisagenlecleucel/ARI-0001). Biomarkers were higher in those who needed inotropic or respiratory support.ConclusionsPCT levels increase after CAR-T cell therapy in the setting of systemic inflammation and could be a predictor of PICU admission and evolution to death. Further research studying its role in the context of CRS and the differential diagnosis between infection and CRS is needed to better understand the biology of this biomarker and to define its value in clinical practice.
Journal • IO biomarker
|
CRP (C-reactive protein)
|
Kymriah (tisagenlecleucel-T) • Qartemi (varnimcabtagene autoleucel)
3ms
T cell malignancies after CAR T cell therapy in the DESCAR-T registry. (PubMed, Nat Med)
Of the 3,066 patients included (2,536 B cell lymphoma, 162 B cell acute lymphoblastic leukemia (ALL) and 368 multiple myeloma), 1,680 (54.8%) received axicabtagene ciloleucel, 205 (6.7%) brexucabtagene autoleucel, 44 (1.4%) lisocabtagene maraleucel and 769 (25.1%) tisagenlecleucel. All multiple myeloma patients received idecabtagene vicleucel, with none receiving ciltacabtagene autoleucel...Thus, the development of this secondary T cell malignancy might be linked to the use of CAR T cell therapy. In conclusion, our findings indicate a very low risk of T cell malignancy after CAR T cell therapy.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK negative
|
Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel)
3ms
Study of E7777 Prior to Kymriah for R/R DLBCL (clinicaltrials.gov)
P1/2, N=30, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
MYC expression
|
Kymriah (tisagenlecleucel-T) • Lymphir (denileukin diftitox-cxdl)
3ms
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome. (PubMed, Haematologica)
At day+1, higher plasma levels of lipid metabolism products and lower glucose and glycoproteins levels were observed in tisa-cel compared to axi-cel-treated patients. Our data show complex metabolomic changes that track the evolution of the disease and drug activity in the first 30 days of CAR-T cell therapy. Conceivably, a pro-inflammatory drift may be linked to a forthcoming disease relapse in CAR-T patients.
Clinical data • Journal • CAR T-Cell Therapy • IO biomarker
|
CRP (C-reactive protein)
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T)
4ms
Dynamics of Immune Reconstitution and Impact on Outcomes Across CAR-T Cell Products in Large B-Cell Lymphoma. (PubMed, Blood Cancer Discov)
Here, we profiled IR in 263 patients with relapsed/refractory large B-cell lymphoma receiving CAR-T therapy (axicabtagene ciloleucel 44.9%, lisocabtagene maraleucel 30.4%, tisagenlecleucel 24.7%). IR differences exist by product, with fastest CD4+ T cell recovery seen for tisagenlecleucel, driven primarily by more rapid recovery of the CD4+CCR7-45RA- effector memory subset. Natural killer cell, but not CD4+ T cell, recovery is significantly associated with favorable progression-free (HR: 0.647; 95% CI: 0.476-0.880) and overall survival (HR: 0.637; 95% CI: 0.441-0.920) and inversely correlated with inflammatory markers measured at time of infusion.
Journal • CAR T-Cell Therapy • IO biomarker
|
CD4 (CD4 Molecule) • CCR7 (Chemokine (C-C motif) receptor 7)
|
Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T)
4ms
Aggressive Lymphoma after CD19 CAR T-Cell Therapy. (PubMed, N Engl J Med)
The development of a fatal, clonal, autonomously proliferating CD4-CD8- chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment with tisagenlecleucel for relapsed primary central nervous system lymphoma. Somatic DNMT3A and TET2 mutations in CD34+ stem cells and their progeny were detected in the PTCL, in the apheresis specimen that was obtained for CAR T-cell production, and in the autotransplant. The PTCL harbored an additional somatic TET2 mutation, which was already detectable in the CAR T-cell apheresis product and the final CAR T-cell product at very low frequencies, providing evidence that clonal hematopoiesis had contributed to lymphomagenesis.
Journal • CAR T-Cell Therapy • IO biomarker
|
DNMT3A (DNA methyltransferase 1) • CD8 (cluster of differentiation 8) • TET2 (Tet Methylcytosine Dioxygenase 2) • CD34 (CD34 molecule)
|
TET2 mutation
|
Kymriah (tisagenlecleucel-T) • HD-CAR-1
5ms
LOKI: Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah (clinicaltrials.gov)
P1, N=0, Withdrawn, University Health Network, Toronto | N=40 --> 0 | Recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV
5ms
Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update (ASH 2024)
Correlative analyses suggest that most baseline high-risk disease characteristics (double-refractory disease, bulky disease, POD24, and high FLIPI) are not associated with inferior efficacy following tisagenlecleucel infusion in pts with r/r FL. Furthermore, high frequencies of MRD-negative status were achieved in a subset of evaluable pts.
Clinical data • P2 data • Clinical • IO biomarker
|
clonoSEQ
|
Kymriah (tisagenlecleucel-T)
5ms
Trial completion date
|
Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Kymriah (tisagenlecleucel-T)
6ms
Addition of nivolumab tailored by expansion of CAR-T cells in patients with stable/progressive large B cell lymphoma at lymphodepletion - a phase 2, prospective interventional study. (PubMed, Transplant Cell Ther)
We conclude that the addition of nivolumab based on CAR-T cell expansion in patients with SD/PD-LBCL is safe and yields promising early response rates.
P2 data • Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD27 (CD27 Molecule)
|
PD-1 expression
|
Opdivo (nivolumab) • Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T)
6ms
Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab. (PubMed, Antibodies (Basel))
CAR-MNZ bearing the CD28-OX40-CD3ζ signaling modules, and CAR-BG2, designed on the Tisagenlecleucel CAR sequence (Kymriah®), carrying the 4-1BB and CD3ζ signaling elements, were employed. CIK + Blina displayed strongest NFAT and IFN-ɣ induction, whereas CARCIK-BG2 demonstrated superior synapse formation. All the effectors have shown therapeutic activity in vivo against the CD19+ Daudi tumor model, with CARCIK cells showing a more durable response compared to CIK + Blina, likely due to the short half-life of Blina in this model.
Journal
|
CD19 (CD19 Molecule) • IL2 (Interleukin 2)
|
CD19 expression
|
Blincyto (blinatumomab) • Kymriah (tisagenlecleucel-T)
7ms
Tisagenlecleucel in Primary CNS Lymphoma (clinicaltrials.gov)
P1, N=6, Completed, Matthew J. Frigault, M.D. | Active, not recruiting --> Completed
Trial completion
|
Kymriah (tisagenlecleucel-T)
8ms
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. (PubMed, J Hematol Oncol)
Patients with a CRS-PSS score > 2 had significantly higher risk to develop grade ≥ 3 ICANS. Both scores were externally validated in international cohorts of patients treated with tisa-cel or axi-cel.
Journal • CAR T-Cell Therapy
|
CRP (C-reactive protein)
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T)
8ms
The Kinetics of Inflammation-Related Proteins and Cytokines in Children Undergoing CAR-T Cell Therapy-Are They Biomarkers of Therapy-Related Toxicities? (PubMed, Biomedicines)
This study was a prospective analysis of proinflammatory proteins and cytokines in children treated with tisagenlecleucel...None of the toxicities were fatal. All of the analyzed biomarkers rose within 14 days after CAR-T infusion, with most reaching their maximum around the third day following the procedure.
Journal • CAR T-Cell Therapy • IO biomarker
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL10 (Interleukin 10) • CRP (C-reactive protein)
|
Kymriah (tisagenlecleucel-T)
8ms
CASSIOPEIA: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (clinicaltrials.gov)
P2, N=121, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
Enrollment closed • Minimal residual disease
|
CD19 (CD19 Molecule)
|
Kymriah (tisagenlecleucel-T)
9ms
Activated CD4+ T Cell Proportion in the Peripheral Blood Correlates with the Duration of Cytokine Release Syndrome and Predicts Clinical Outcome after Chimeric Antigen Receptor T Cell Therapy. (PubMed, Intern Med)
Conclusion These results suggest that the proportion of activated CD4+ T cells on day 7 after tisa-cel infusion correlates with the CRS duration and predicts clinical outcomes after CAR T cell therapy. Further studies with a larger number of patients are required to validate these observations.
Clinical data • Retrospective data • Journal • CAR T-Cell Therapy
|
IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL7R (Interleukin 7 Receptor) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
|
Kymriah (tisagenlecleucel-T)
10ms
Malnutrition and cachexia are associated with poor CAR T-cell therapy outcomes including survival. (PubMed, Clin Nutr ESPEN)
Pre-treatment malnutrition and cachexia was significantly associated with adverse CAR T patient outcomes, including mGPS cachexia status independently associated with inferior overall survival. Further research in this novel space is essential to confirm the extent and impact of nutritional issues, to assist with implementing dietetic pathways, and to identify potential interventions with a view to optimising outcomes.
Journal • CAR T-Cell Therapy
|
CRP (C-reactive protein)
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T)
10ms
LOKI: Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah (clinicaltrials.gov)
P1, N=40, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy
|
cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV
11ms
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies (clinicaltrials.gov)
P1, N=20, Recruiting, Stanford University | Not yet recruiting --> Recruiting
Enrollment open
|
CD22 (CD22 Molecule)
|
Kymriah (tisagenlecleucel-T) • firicabtagene autoleucel (CRG-022)
11ms
New P1 trial • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
Kymriah (tisagenlecleucel-T) • firicabtagene autoleucel (CRG-022)
11ms
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel. (PubMed, J Hematol Oncol)
Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CART products idecabtagene vicleucel and ciltacabtagene autoleucel. Neutropenia ≥ grade 3 was observed in 29.0% of patients; thrombocytopenia ≥ grade 3 occurred in 9.7%. In conclusion, bendamustine lymphodepletion before liso-cel appears to be a strategy that can drive tumor responses while ensuring a mild toxicity profile.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • bendamustine • Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel)
12ms
Early CAR- CD4+ T-lymphocytes recovery following CAR-T cell infusion: A worse outcome in diffuse large B cell lymphoma. (PubMed, EJHaem)
Among possible determinants of CD4+ T cell recovery, we recognized infusion of a 4-1BB product (tisagenlecleucel, TSA) in comparison with a CD28 (axicabtagene/brexucabtagene, AXI/BRX) (hazard ratio [HR] [95% CI]: 5.79 [1.16-24.12] p = 0.016). We conclude that a faster CAR- CD4+ T cell recovery is associated with TSA as compared to AXI/BRX. Month-1 CAR- CD4+ T cell subset recovery could represent a "red flag" for CAR-T cell therapy failure in DLBCL patients.
Journal • CAR T-Cell Therapy
|
CD4 (CD4 Molecule)
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T) • Tecartus (brexucabtagene autoleucel)
12ms
Tisagenlecleucel In Primary CNS Lymphoma (clinicaltrials.gov)
P1, N=6, Active, not recruiting, Matthew J. Frigault, M.D. | Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Dec 2024
Enrollment closed • Trial completion date
|
Kymriah (tisagenlecleucel-T)
12ms
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=396, Recruiting, SWOG Cancer Research Network | Trial primary completion date: Dec 2024 --> Dec 2025
Trial primary completion date • CAR T-Cell Therapy
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
1year
B-cell-directed CAR-T cell therapy activates CD8+ cytotoxic CARneg bystander T-cells in non-human primates and patients. (PubMed, Blood)
A transcriptionally similar population was identified in patients following Tisagenlecleucel infusion...In vitro activated and patient-derived T-cells with the bystander phenotype efficiently killed leukemic cells through a TCR-independent mechanism. Collectively, this dataset provides the first comprehensive identification and profiling of CARneg bystander CD8+ T-cells following B-cell targeting CAR-T cell therapy and suggests a novel mechanism through which CAR-T cell infusion might trigger enhanced anti-leukemic responses.
Journal • CAR T-Cell Therapy • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • IL2 (Interleukin 2) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • IL15 (Interleukin 15) • KLRD1 (Killer Cell Lectin Like Receptor D1)
|
Kymriah (tisagenlecleucel-T)
1year
MT2017-45: CAR-T Cell Therapy for Heme Malignancies (clinicaltrials.gov)
P=N/A, N=144, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Recruiting --> Active, not recruiting | N=240 --> 144 | Trial primary completion date: Jun 2028 --> Feb 2024
Enrollment closed • Enrollment change • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel)
1year
LOKI: Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah (clinicaltrials.gov)
P1, N=40, Not yet recruiting, University Health Network, Toronto | Initiation date: Dec 2023 --> Apr 2024
Trial initiation date • CAR T-Cell Therapy
|
cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV
1year
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy (clinicaltrials.gov)
P1, N=57, Recruiting, NeoImmuneTech | Phase classification: P1b --> P1
Phase classification
|
Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • Hyleukin-7 (efineptakin alfa)
1year
New trial
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T)
1year
Study of Out of Specification for Tisagenlecleucel (clinicaltrials.gov)
P3, N=200, Recruiting, Novartis Pharmaceuticals | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Apr 2025
Trial completion date • Trial primary completion date
|
Kymriah (tisagenlecleucel-T)
1year
An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. (PubMed, Cell Rep Med)
We identify an upregulation of CD80 and/or CD86 in tumor tissue of (r/r) diffuse large B cell lymphoma (DLBCL) patients treated with tisagenlecleucel...In addition, immunocompetent mice show an intact CD80-CD19+ B cell population after CAR/CCR T cell treatment. The results reveal the CAR/CCR design as a promising strategy for further translational study.
Journal • CAR T-Cell Therapy
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
|
CTLA4 expression
|
Kymriah (tisagenlecleucel-T)
1year
Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition. (PubMed, Cell Death Dis)
We realized the translational relevance of these findings by examining the scRNA-seq profiles of Tisa-cel and Axi-cel infusion products and show a significant correlation between GZMB and GZMA expression at the single-cell level in a T cell subset-dependent manner. Our findings highlight the importance of the redundancy in killing mechanisms of CAR T cells and how this redundancy is important for efficacious T cells.
Journal
|
FASLG (Fas ligand) • GZMB (Granzyme B) • GZMA (Granzyme A)
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T)